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Abstract 
Schizophrenia is a common and severe mental illness affecting several domains of 
cognition and behaviour. The illness most frequently becomes manifest in early 
adulthood, and often follows a chronic course. It is associated with high morbidity and 
mortality, and is a leading contributor to disease burden, health and social care costs 
throughout the world.  
 
Antipsychotics are the mainstay of treatment but are limited by significant adverse 
effects, and therapeutic options for many patients remain inadequate. Schizophrenia is 
associated with a range of adverse physical health outcomes, which may be 
compounded by lifestyle factors including substance use, barriers in accessing 
healthcare, and the adverse effects of treatment. Psychological and social interventions 
are a crucial element of patient care, particularly in alleviating negative symptoms. 
 
Current theories view schizophrenia as a disorder of early brain development with 
interacting genetic and environmental risk factors. 
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Definition 
Schizophrenia is a mental illness characterized by positive symptoms (delusions, 
hallucinations, thought disorder and disorganised behaviour), negative symptoms 
(social withdrawal and apathy) and cognitive symptoms (poor executive function and 
memory).  It frequently follows a chronic course and is associated with a decline in 
social and occupational functioning. ICD-10 criteria for schizophrenia are listed in table 
1, and require a symptom duration of at least one month. 
 
Epidemiology 
The prevalence and incidence of schizophrenia vary widely depending on the location 
and the diagnostic definition that is employed. Whilst it is often quoted that 1 in 100 of 
the population will have schizophrenia in their lifetime, studies suggest that the global 
average lifetime prevalence is somewhat lower, at 0.72%1. In a study of incidence of 
schizophrenia in England from 1997 to 1999, the age-adjusted incidence in Bristol was 
7.2, Nottingham 7.6, and SE London 20.1 cases per 100,000 person-years suggesting 
geographical heterogeneity in underlying biological, psychological and environmental 
risk factors. The average general practitioner can expect to see around one new case 
per year, and have between five and 10 patients with the diagnosis on their caseload. 
 
Schizophrenia usually emerges in late adolescence or early adulthood, with women 
having a later average age of onset compared with men. Onset is rare before the age of 
16, and uncommon after the age of 50. 
 
Pathophysiology 
The dopamine hypothesis has played a central role in neurobiological theories of 
schizophrenia. Support comes from the observation that drugs such as amphetamines, 
which stimulate dopamine release, can induce psychosis, and that all antipsychotic 
drugs exert antagonism to D2 dopamine receptors, with the degree of antagonism 
correlating with the therapeutic dose. PET and MRI ligand studies have demonstrated 
increased presynaptic dopamine synthesis and release during acute psychosis. 
However, approximately a third of patients show a limited response to antipsychotic 
treatment, and recent findings suggest that this subgroup may not exhibit dopaminergic 
dysfunction.  
 
MRI studies have shown an overall decrease in brain volume of 3–4%, with particular 
differences in the volume of the hippocampi and thalamus, and enlargement of the 
lateral ventricles. At a cytoarchitectural level, an absence of gliosis and other correlates 
of cell injury or death strongly argue that schizophrenia is not due to a 
neurodegenerative process. 
 
Aetiology 
A concept that has gained widespread currency is the neuro-developmental 
hypothesis of schizophrenia, which proposes that although the overt phase of illness is 
usually of adult onset, its roots lie in the preceding stages of brain development. The 
pathogenesis of schizophrenia is considered to be dependent upon the interplay 
between genetic vulnerability, environmental and social factors2. 
 
Genetic vulnerability 
Monozygotic twin concordance rates for schizophrenia of about 50% point to a 
significant genetic basis, and current estimates suggest an overall heritability of around 
80%. Nonetheless, most individuals who have been diagnosed with schizophrenia have 
no family history of psychosis, and no single genes have been identified, suggesting 
that many risk alleles of small effect size are involved. A landmark genome-wide 
association study (GWAS) identified 108 loci conferring risk for the disorder3, with 
notable associations with the DRD2 dopamine-receptor gene and the major 
histocompatability complex (MHC) coding region, suggesting a role for the immune 
system in schizophrenia. A recent study provided further support for this hypothesis by 
demonstrating specific associations with the C4 complement gene and schizophrenia 
risk.  
 
Polymorphisms in genes involved in neuronal migration (DISC1), synaptogenesis 
(neurexin family), and glutamate transmission (GAD67/GAD1) have also received 
attention. New techniques that are able to detect deletions and duplications of 
chromosomal segments, known as copy number variants (CNVs), have revealed an 
over-representation of CNVs in schizophrenia, particularly in regions carrying genes 
involved in neuronal development. Recent studies have also demonstrated a shared 
genetic liability for schizophrenia and bipolar disorder, suggesting an aetiological 
continuum between the disorders.  
 
Gestational and perinatal exposures 
A wide variety of prenatal exposures, such as viral or bacterial infection, stress and 
malnutrition, and perinatal variables, such as low birth weight, prematurity, prolonged 
labour and neonatal hypoxia, have demonstrated associations with an increased risk of 
schizophrenia. An intriguing finding is the modest but consistently raised incidence of 
schizophrenia among individuals born in winter months, which may be causally related 
to seasonal variation in rates of intrauterine viral infection. 
 
Urbanicity, immigration and social adversity 
Urban upbringing is associated with a more than 2-fold increase in risk of schizophrenia 
compared to rural settings, in a dose-dependent fashion. Various lines of evidence 
suggest this is not explained by a ‘drift effect’ of genetically vulnerable individuals 
moving to an urban setting, but rather to factors related to urban living, such as the 
physical environment and social disadvantage. 
 
Consistently increased rates of schizophrenia are seen in first- and second generation 
immigrants above that of non-migrants. It has been shown that the risk of developing 
schizophrenia is decreased among minority ethnic groups living in areas with a higher 
density of their own ethnic group, suggesting that the degree to which one occupies a 
minority position, with the associated experiences of chronic social inferiority and 
marginalization, might be of aetiological importance. 
 
Substance use 
An expanding literature supports the hypothesis that cannabis increases the risk of 
developing schizophrenia. A systematic review found a dose-dependent increase in risk 
of long-term psychotic outcomes among those who had ever (odds ratio 1.41) or 
frequently (odds ratio 2.09) used cannabis. Recent research has identified a three-times 
excess risk among users of high-potency ‘skunk’, a form of cannabis containing a 
greater proportion of the active ingredient, tetrahydrocannabinol, than traditional 
marijuana. Amphetamines, LSD, ecstasy and ketamine ingestion have also been 
implicated in the precipitation of psychotic states. 
 
Clinical features and course 
The syndrome of schizophrenia can be divided into positive or negative symptom 
dimensions. Additionally, frank onset of illness is often preceded by a sub-clinical 
prodromal state, commonly of several weeks to months' duration, characterized by 
social and occupational withdrawal, loss of interest in activities, change in personality, 
altered mood and paranoid ideas. Progression to psychosis and the subsequent mode 
of presentation to psychiatric services is often with bizarre or disinhibited behaviour, 
deliberate self-harm or attempted suicide, intoxication, or police involvement. 
 
Positive symptoms are those that are seen during the acute psychotic state, and are 
characterized by disturbance in a broad range of cognitive functions, including a loss of 
the normal flow of thinking, usually demonstrated in the patient's speech (formal thought 
disorder), delusions, often of a paranoid nature, a loss of sense of agency over thoughts 
and actions (passivity phenomena) and hallucinations, often in the form of hearing 
voices. 
 
The negative symptom cluster is an enduring aspect, most often interposed between, 
and co-existing with, episodes of acute psychosis. It reflects a defect state affecting 
several neurocognitive domains, characterized by impairments in motivation and willed 
action, blunted and flat affect, anhedonia, poverty of thought and speech, poor self-care 
and loss of appropriate social interaction. It is a highly disabling aspect of the illness, not 
least due to its chronicity. 
 
A less overt but equally disabling core feature of schizophrenia is the associated 
cognitive deficit. Patients with schizophrenia perform on average 0.5-1 standard 
deviation below controls in a broad range of cognitive domains, with particular deficits in 
frontal lobe function, attention and processing speed, although 20-30% of patients are 
cognitively intact. Where cognitive deficits do exist, they appear to be relatively chronic 
and independent of positive symptoms, and can impact profoundly upon an individual's 
social and occupational function. 
 
Assessment and diagnosis 
There are no reliable pathophysiological markers of schizophrenia, and diagnosis is 
therefore made clinically through the identification of the characteristic syndrome. The 
ICD-10 criteria for diagnosis are set out in (Table 1). ICD-10 and DSM-IV classification 
systems have historically split schizophrenia into simple, paranoid, hebephrenic and 
catatonic subtypes, but these have been removed from DSM-5 due to their limited 
diagnostic stability and clinical utility. 
 
Assessment should begin with a comprehensive psychiatric, medical and social history, 
and collateral information is often invaluable. Physical examination, including a thorough 
neurological examination to identify organic pathology, is essential, and cognitive 
function should be examined where possible. Routine blood tests including baseline 
lipid and glycaemic profile are indicated, and an ECG and urine drug screen should be 
obtained. In a first presentation of psychosis, testing for antibodies against the N-
methyl-D-aspartate (NMDA) receptor and voltage-gated potassium channel complex is 
gaining increasing acceptance. MR imaging and EEG are indicated if an organic cause 
is suspected. The differential diagnosis for a psychotic presentation is outlined in (Table 
2). Assessment should be made of the patient's level of insight into their illness, 
capacity to consent to treatment, and risk to self and others, and a plan for hospital 
admission made accordingly. 
 
Prognosis 
Following a first episode of psychosis, reasonable control of psychotic symptoms can be 
achieved in over 80% of patients, with effective treatment. However, without 
maintenance antipsychotic medication, more than 90% of patients will relapse, 
highlighting the critical importance of long-term treatment in improving outcome. 
 
Making accurate predictions about clinical course in individual patients is challenging, 
and outcomes are highly heterogeneous. Studies after first episodes of psychosis have 
broadly shown that, with treatment, around 20% of patients will fully recover with a good 
functional outcome, 35% will experience a relapsing and remitting illness with good 
function in between episodes, and another 35% will have chronic positive and negative 
symptoms requiring ongoing community care. Around 10% will suffer severe chronic 
symptoms, requiring long-term inpatient treatment or residential care, often involving 
forensic services. 
 
Schizophrenia is associated with a 15-year average reduction in life-expectancy. 
Suicide accounts for 40% of the excess mortality, with 5–10% of patients eventually 
dying by suicide. More than half of suicides occur in the first 5 years of illness, making 
individuals recovering from their first episode of psychosis a particularly high-risk group.  
 
The remaining 60% of the excess in mortality is accounted for by physical health 
problems4. Infectious, cardio-respiratory, metabolic, musculoskeletal, and endocrine 
disease are more frequent in schizophrenia than in the general population. Though 
some of these poor outcomes can be explained by behaviours relating to schizophrenia 
(e.g. smoking and inactivity secondary to negative symptoms) and its treatment with 
psychotropic medication, a neglected factor is the disparity in healthcare access, 
utilisation and provision. People with schizophrenia are less likely to receive the same 
standards of care for physical disorders than individuals without mental illness, a result 
of stigma and ‘diagnostic overshadowing’ – the assumption that physical complaints are 
psychosomatic symptoms arising from mental illness.  
 
Despite this somewhat pessimistic outlook, careful formulation and case management 
at an individual level, good communication and education with patients and their 
families, and an emphasis on the importance of continuing to take medication when 
required can improve considerably quality of life and longer term outcomes. 
 
Management 
Schizophrenia can be a bewildering, distressing and stigmatizing illness for patients and 
their carers, and necessitates a compassionate, multi-disciplinary approach. In the UK, 
emphasis is placed on managing patients with schizophrenia in the community, with 
delivery of care by community mental health teams, crisis teams and day hospitals. 
Where necessary, admission is made to hospital for assessment and treatment, often 
with compulsion under sections 2 and 3 of the Mental Health Act. 
 
All people with first presentation of psychotic symptoms should be referred urgently for 
assessment by a secondary care level, local community-based mental health service. 
Where available, direct referral should be made to services specializing in early 
intervention in psychosis. 
 
Pharmacological interventions 
The goals of pharmacotherapy in schizophrenia are to minimize symptoms and 
functional impairment, reduce rate of relapse and hospital admission, whilst at the same 
time keeping adverse effects to a minimum. Antipsychotics are effective in treating 
positive symptoms, but are at best only partially effective in treating the negative 
symptoms of schizophrenia. Drugs that block postsynaptic D2 dopamine receptors have 
formed the mainstay of treatment for schizophrenia; these have traditionally been 
divided into first generation antipsychotics, such as sulpiride and haloperidol, and newer 
second generation agents, such as olanzapine and risperidone. Oral short- and long-
acting (depot) injection preparations are available in both groups, and are generally 
reserved for cases where adherence with oral medication is poor. 
 
First generation agents primarily exert antagonism at the D2 receptor together with 
antagonism at muscarinic cholinergic, histaminergic and α-1 adrenergic receptors, 
whereas second generation antipsychotics have a broader receptor profile, 
antagonizing central serotonergic receptors as well as blocking a range of dopamine 
receptors more weakly. Their adverse-effect profiles are therefore different, with first 
generation drugs tending to cause troublesome extrapyramidal effects (EPSEs) such as 
dystonia, bradykinesia and akathisia, through blockade of nigrostriatal D2 receptors. 
Second generation antipsychotics cause fewer motor adverse effects, but predispose to 
the metabolic syndrome, including weight gain, dyslipidaemia, hyperprolactinemia and 
glucose intolerance. Treatment with any antipsychotic drug therefore often comes at a 
significant cost. Common adverse effects associated with antipsychotic treatment are 
set out in the article on Antipsychotics in Psychiatry II (Medicine xxx, xxx). 
 
Large randomized controlled trials comparing first and second generation antipsychotics 
have challenged the belief that second generation agents are more effective at treating 
the positive and negative symptoms of schizophrenia. The CATIE (USA) and CUtLASS 
1 (UK) trials demonstrated lack of superiority of second generation over first generation 
agents in terms of symptom and quality-of-life scores. A recent meta-analysis5 illustrates 
however that although antipsychotics show only small differences in efficacy, they differ 
substantially in their propensity to cause side-effects that lead to treatment 
discontinuation, and reinforces how choice of treatment should be tailored to the needs 
of the individual patient.  
 
Around 30% of patients fail to respond significantly to two or more antipsychotics, and 
are therefore considered to have ‘treatment-resistant’ illness. 30-50% of treatment –
resistant patients will respond to clozapine, making it an important and unique second-
line treatment. However, 0.5–1% of patients develop potentially fatal clozapine-induced 
agranulocytosis; registration with a monitoring service and monthly blood testing is 
therefore mandatory for patients receiving clozapine. Other serious and often 
overlooked side-effects include aspiration pneumonia, neuroleptic malignant syndrome 
(NMS), ileus and myocarditis. 
 
Social and psychological interventions 
Modern community services for patients with schizophrenia are organized with the aim 
of providing treatment and rehabilitation through the use of case management (care 
programme approach or CPA) and assertive community treatment services. Assisting 
patients in finding appropriate accommodation, and working to promote education and 
supported employment are key goals of these agencies. 
 
Family therapy aimed at educating relatives about the illness and its management, and 
altering attitudes and behaviour relating to it, is recommended by NICE for all patients 
with schizophrenia. 
 
Emerging evidence points to the utility of combining medication with psychological 
interventions, particularly cognitive behavioural therapy (CBT) and family interventions, 
in improving clinical outcomes. In particular, CBT has been shown to lead to long-term 
reduction in the intensity and distress associated with treatment-resistant delusions and 
hallucinations. There is also evidence for use of psychological treatments in improving 
medication adherence and preventing relapse. 
  
 
Key points 
 
 Schizophrenia is a complex and chronic illness requiring a co-ordinated multi-
disciplinary approach. 
 Early referral and treatment should be established in first presentation of 
psychosis. 
 Oral antipsychotics should be offered following a discussion with the patient of 
the relative risks and benefits. Polypharmacy should be avoided, and medication 
should be continued at the lowest effective dose. 
 Cognitive behavioural therapy should be offered to all patients, and family 
therapy to relatives of people with schizophrenia. 
 Mortality in schizophrenia is twice that of the general population; co-morbid 
physical illness is over-represented as a result of lifestyle factors, effects of 
medication, and requires recognition and treatment. 
 Individuals with schizophrenia should be treated in a non-judgemental and 
compassionate manner, with emphasis on promoting recovery and reducing 
stigma amongst patients, carers and the public. 
  
Table 1: ICD-10 criteria for schizophrenia (F20)a  
 
• At least one of the following: 
○ Thought echo, thought insertion or withdrawal, or thought broadcast 
○ Delusions of control, influence or passivity, clearly referred to body or limb 
movements or specific thoughts, actions, or sensations; delusional perception 
○ Hallucinatory voices giving a running commentary on the patient's behaviour, 
or discussing him between themselves, or other types of hallucinatory voices 
coming from some part of the body 
○ Persistent delusions of other kinds that are culturally inappropriate and 
implausible (e.g. being persecuted by a network of government agents; being an 
emissary from another world) 
 
• Or at least two of the following: 
○ Persistent hallucinations in any modality, when occurring every day for at least 
a month, when accompanied by fleeting or half-formed delusions without a clear 
affective component, or when accompanied by persistent over-valued ideas 
○ Neologisms, breaks or interpolations in the train of thought, resulting in 
incoherence or irrelevant speech 
○ Catatonic behaviour, such as excitement, posturing or waxy flexibility, 
negativism, mutism and stupor 
○ Negative symptoms such as marked apathy, paucity of speech, and blunting or 
incongruity of emotional responses 
 
• Duration of the above symptoms for at least 1 month. 
 
a ICD-10 classification of mental and behavioural disorders, diagnostic criteria for 
research.14 
 
 
  
Table 2: Differential diagnosis for psychotic episode (more common 
diagnoses listed first) 
Functional Organic 
Affective psychosis (mania or 
depression with psychotic features) 
(F30–39) 
Delirium, including alcohol withdrawal 
state and metabolic or endocrine 
derangement 
Schizo-affective disorder (F25) Medication-induced psychosis (including 
corticosteroids, antihistamines, dopamine 
agonists, sympathomimetics) 
Substance-induced psychotic 
disorder (including alcohol, 
stimulants, hallucinogens) (F10.5–
19.5) 
Autoimmune encephalitis (e.g. VGKC and 
NMDA receptor antibody mediated) 
Persistent delusional disorder (F22) Neurodegenerative conditions (e.g. 
Alzheimer's disease, Wilson's disease) 
Acute transient psychotic disorder 
(F23) 
Epilepsy: post-ictal and inter-ictal 
psychosis; particularly temporal lobe 
seizures 
Schizotypal personality disorder 
(F22) 
Brain injury 
Paranoid personality disorder 
(F60.0) 
CNS neoplasm 
 
Induced/shared psychotic disorder 
(folie a deux) (F24) 
CNS infection (e.g. neurosyphilis, HIV 
seroconversion, herpes encephalitis) 
Factitious disorder (F68.1) Systemic lupus erythematosus 
 Multiple sclerosis 
 
CNS, central nervous system; HIV, human immunodeficiency virus; NMDA, N-
methyl-D-aspartic acid; VGKC, voltage-gated potassium channel. 
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